Salvatore Scali1, Virendra Patel2, Daniel Neal3, Daniel Bertges4, Karen Ho5, Jens-Eldrup Jorgensen6, Jack Cronenwett7, Adam Beck3. 1. Division of Vascular Surgery and Endovascular Therapy, University of Florida, Gainesville, Fla. Electronic address: salvatore.scali@surgery.ufl.edu. 2. Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Mass. 3. Division of Vascular Surgery and Endovascular Therapy, University of Florida, Gainesville, Fla. 4. Division of Vascular Surgery, University of Vermont, Burlington, Vt. 5. Division of Vascular Surgery, Northwestern University, Chicago, Ill. 6. Vascular Center, Maine Medical Center, Portland, Me. 7. Heart and Vascular Center, Darmouth-Hitchcock Medical Center, Lebanon, NH.
Abstract
OBJECTIVE: Routine initiation β-blocker medications before vascular surgery is controversial due to conflicting data. The purpose of this analysis was to determine whether prophylactic use of β-blockers before major elective vascular surgery decreased postoperative cardiac events or mortality. METHODS: The Society for Vascular Surgery Vascular Quality Initiative (SVS-VQI) data set was used to perform a retrospective cohort analysis of infrainguinal lower extremity bypass (LEB), aortofemoral bypass (AFB), and open abdominal aortic aneurysm (AAA) repair patients. Chronic (>30 days preoperatively) β-blocker patients were excluded, and comparisons were made between preoperative (0-30 day) and no β-blocker groups. Patients were risk stratified using a novel prediction tool derived specifically from the SVS-VQI data set. Propensity-matched pairs and interprocedural specific risk stratification comparisons were performed. End points included in-hospital major adverse cardiac events (MACEs), including myocardial infarction (MI; defined as new ST or T wave electrocardiographic changes, troponin elevation, or documentation by echocardiogram or other imaging modality), dysrhythmia, and congestive heart failure, and 30-day mortality. RESULTS: The study analyzed 13,291 patients (LEB, 68% [n = 9047]; AFB, 11% [n = 1474]; and open AAA, 21% [n = 2770]); of these, 67.7% (n = 8999) were receiving β-blockers at time of their index procedure. Specifically, 13.2% (n = 1753) were identified to have been started on a preoperative β-blocker, 54.5% (n = 7426) were on chronic β-blockers, and 32.3% (n = 4286) were on no preoperative β-blockers. Among the three procedures, patients had significant demographic and comorbidity differences and thus were not combined. A 1:1 propensity-matched pairs analysis (1459 pairs) revealed higher rates of postoperative MI with preoperative β-blockers (preoperative β-blocker relative risk, 1.65; 95% confidence interval, 1.02-2.68; P = .05 vs no β-blocker), with no difference in dysrhythmia, congestive heart failure, or 30-day mortality. When stratified into low-risk, medium-risk, and high-risk groups within each procedure, all groups of preoperative β-blocker patients had no difference or higher rates of MACEs and 30-day mortality, with the exception of high-risk open AAA patients, who had a lower rate of MI (odds ratio, 0.35; 95% confidence interval, 011-0.87; P = .04). CONCLUSIONS: Exclusive of high-risk open AAA patients, preoperative β-blockers did not decrease rates of MACEs or mortality after LEB, AFB, or open AAA. Importantly, exposure to prophylactic preoperative β-blockers increased the rates of some adverse events in several subgroups. Given these data, the SVS-VQI cannot support routine initiation of preoperative β-blockers before major elective vascular surgery in most patients.
OBJECTIVE: Routine initiation β-blocker medications before vascular surgery is controversial due to conflicting data. The purpose of this analysis was to determine whether prophylactic use of β-blockers before major elective vascular surgery decreased postoperative cardiac events or mortality. METHODS: The Society for Vascular Surgery Vascular Quality Initiative (SVS-VQI) data set was used to perform a retrospective cohort analysis of infrainguinal lower extremity bypass (LEB), aortofemoral bypass (AFB), and open abdominal aortic aneurysm (AAA) repair patients. Chronic (>30 days preoperatively) β-blockerpatients were excluded, and comparisons were made between preoperative (0-30 day) and no β-blocker groups. Patients were risk stratified using a novel prediction tool derived specifically from the SVS-VQI data set. Propensity-matched pairs and interprocedural specific risk stratification comparisons were performed. End points included in-hospital major adverse cardiac events (MACEs), including myocardial infarction (MI; defined as new ST or T wave electrocardiographic changes, troponin elevation, or documentation by echocardiogram or other imaging modality), dysrhythmia, and congestive heart failure, and 30-day mortality. RESULTS: The study analyzed 13,291 patients (LEB, 68% [n = 9047]; AFB, 11% [n = 1474]; and open AAA, 21% [n = 2770]); of these, 67.7% (n = 8999) were receiving β-blockers at time of their index procedure. Specifically, 13.2% (n = 1753) were identified to have been started on a preoperative β-blocker, 54.5% (n = 7426) were on chronic β-blockers, and 32.3% (n = 4286) were on no preoperative β-blockers. Among the three procedures, patients had significant demographic and comorbidity differences and thus were not combined. A 1:1 propensity-matched pairs analysis (1459 pairs) revealed higher rates of postoperative MI with preoperative β-blockers (preoperative β-blocker relative risk, 1.65; 95% confidence interval, 1.02-2.68; P = .05 vs no β-blocker), with no difference in dysrhythmia, congestive heart failure, or 30-day mortality. When stratified into low-risk, medium-risk, and high-risk groups within each procedure, all groups of preoperative β-blockerpatients had no difference or higher rates of MACEs and 30-day mortality, with the exception of high-risk open AAA patients, who had a lower rate of MI (odds ratio, 0.35; 95% confidence interval, 011-0.87; P = .04). CONCLUSIONS: Exclusive of high-risk open AAA patients, preoperative β-blockers did not decrease rates of MACEs or mortality after LEB, AFB, or open AAA. Importantly, exposure to prophylactic preoperative β-blockers increased the rates of some adverse events in several subgroups. Given these data, the SVS-VQI cannot support routine initiation of preoperative β-blockers before major elective vascular surgery in most patients.
Authors: Lee A Fleisher; Joshua A Beckman; Kenneth A Brown; Hugh Calkins; Elliott Chaikof; Kirsten E Fleischmann; William K Freeman; James B Froehlich; Edward K Kasper; Judy R Kersten; Barbara Riegel; John F Robb; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Elliott M Antman; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Sharon A Hunt; Bruce W Lytle; Rick Nishimura; Richard L Page; Barbara Riegel Journal: Circulation Date: 2006-06-06 Impact factor: 29.690
Authors: Anne Benedicte Juul; Jørn Wetterslev; Christian Gluud; Allan Kofoed-Enevoldsen; Gorm Jensen; Torben Callesen; Peter Nørgaard; Kim Fruergaard; Morten Bestle; Rune Vedelsdal; André Miran; Jon Jacobsen; Jakob Roed; Maj-Britt Mortensen; Lise Jørgensen; Jørgen Jørgensen; Marie-Louise Rovsing; Pernille Lykke Petersen; Frank Pott; Merete Haas; Rikke Albret; Lise Lotte Nielsen; Gun Johansson; Pia Stjernholm; Yvonne Mølgaard; Nikolai Bang Foss; Jeanie Elkjaer; Bjørn Dehlie; Klavs Boysen; Dusanka Zaric; Anne Munksgaard; Jørn Bo Madsen; Bjarne Øberg; Boris Khanykin; Tine Blemmer; Stig Yndgaard; Grazyna Perko; Lars Peter Wang; Per Winkel; Jørgen Hilden; Per Jensen; Nader Salas Journal: BMJ Date: 2006-06-24
Authors: Lee A Fleisher; Joshua A Beckman; Kenneth A Brown; Hugh Calkins; Elliot L Chaikof; Kirsten E Fleischmann; William K Freeman; James B Froehlich; Edward K Kasper; Judy R Kersten; Barbara Riegel; John F Robb Journal: Circulation Date: 2009-11-02 Impact factor: 29.690
Authors: Paul E Norman; Konrad Jamrozik; Michael M Lawrence-Brown; Max T Q Le; Carole A Spencer; Raywin J Tuohy; Richard W Parsons; James A Dickinson Journal: BMJ Date: 2004-11-15
Authors: Robert J Beaulieu; Danielle C Sutzko; Jeremy Albright; Erin Jeruzal; Nicholas H Osborne; Peter K Henke Journal: JAMA Surg Date: 2020-02-01 Impact factor: 14.766
Authors: Laurel A Grisanti; Anna M Gumpert; Christopher J Traynham; Joshua E Gorsky; Ashley A Repas; Erhe Gao; Rhonda L Carter; Daohai Yu; John W Calvert; Andrés Pun García; Borja Ibáñez; Joseph E Rabinowitz; Walter J Koch; Douglas G Tilley Journal: Circulation Date: 2016-06-30 Impact factor: 29.690